Subtitle
Sparing of the heart facilitates recovery from cardiopulmonary side effects after thoracic irradiation.
Subtitle
Sparing of the heart facilitates recovery from cardiopulmonary side effects after thoracic irradiation.
Proto therapy Time
August 2024
Executive summary
Published in the Red Journal, this study from the Groningen group reported persistent reduction in cardiopulmonary function caused by radiation exposure of the heart and lung during irradiating thoracic tumors in rats. Recovery of the pulmonary vasculature and right ventricle function was observed when sparing the heart from radiation.
Top cancer treatments
Related contents
Proton Therapy Publication
June 2024
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry.
Proton Therapy Publication
July 2024
A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer with Extended Durvalumab Therapy (PARTICLE-D).
Proton Therapy Publication
August 2024
Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing.
Proton Therapy Publication
April 2024
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
Proton Therapy Publication
March 2024
FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach.
Proton Therapy Publication
February 2024
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Proton Therapy Publication
April 2024
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Proton Therapy Publication
May 2023
Outcomes of Patients Treated in the UK Proton Overseas Programme: Non-central Nervous System Group.